RxDoctor Payments DataLook up a doctor →

Alan Glombicki, MD

Obesity Medicine · Houston, TXNPI 1669467395

Payments from drug & device makers

$416,686in general payments, 2019–2025

Across 495 payments — averaging $841.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$162K
  • Takeda Pharmaceuticals U.S.A., Inc.$101K
  • Gilead$81K
  • Sanofi$39K
  • Intercept Pharmaceuticals, Inc.$14K
  • Janssen Research & Development, LLC$11K
  • plus $8K from 21 others

What the payments were for

  • Consulting fees$4,7005%
  • Speaking & faculty fees$66,89072%
  • Travel & lodging$8,97410%
  • Food & beverage$12,57613%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few obesity medicine providers in Texasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$12,039
Medicare patients
34
Services billed
93

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide12$17,046
LinzessLinaclotide22$12,829
Sucralfate104$5,064
Colesevelam Hcl19$3,831
Misoprostol63$3,158
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates32$2,045
Ursodiol12$1,656
Lubiprostone14$909
Peg3350-Sod Sul-Nacl-Kcl-Asb-CPeg3350/Sod Sul/Nacl/Kcl/Asb/C11$747
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl29$509
Clarithromycin12$386
Omeprazole21$221
Metronidazole13$192
Pantoprazole Sodium22$166
Metoclopramide Hcl12$146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$80,714$17,04612 claims
AbbVieLinzess$2,656$12,82922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in Texason file to place this against a meaningful peer group, so we don't.

Other obesity medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →